0 CHECKOUT

Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • ID: 1518944
  • March 2016
  • Region: Global
  • 640 Pages
  • CurrentPartnering
1 of 4

The Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers

The Global Biomarker Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Most active Biomarker dealmakers
2.4. Biomarker partnering by deal type
2.5. Biomarker partnering by therapy area
2.6. Deal terms for Biomarker partnering
2.6.1 Biomarker partnering headline values
2.6.2 Biomarker deal upfront payments
2.6.3 Biomarker deal milestone payments
2.6.4 Biomarker royalty rates

Chapter 3 - Leading Biomarker deals

3.1. Introduction
3.2. Top Biomarker deals by value

Chapter 4 - Most active Biomarker dealmakers

4.1. Introduction
4.2. Most active Biomarker dealmakers
4.3. Most active Biomarker partnering company profiles

Chapter 5 - Biomarker contracts dealmaking directory

5.1. Introduction
5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Biomarker deals by company A-Z

Appendix 2 - Biomarker deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Biomarker deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 - Biomarker deals by therapy area

Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Pediatrics
Psychiatry
Respiratory

Appendix 5 -Deal type definitions

Table of figures

Figure 1: Biomarker partnering since 2010
Figure 2: Active Biomarker dealmaking activity- 2010 to 2016
Figure 3: Biomarker partnering by deal type since 2010
Figure 4: Biomarker partnering by disease type since 2010
Figure 5: Biomarker deals with a headline value
Figure 6: Biomarker deals with an upfront value
Figure 7: Biomarker deals with a milestone value
Figure 8: Biomarker deals with a royalty rate value
Figure 9: Top Biomarker deals by value since 2010
Figure 10: Most active Biomarker dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Note: Product cover images may vary from those shown
3 of 4

Global Biomarker Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of biomarker deal trends since 2010
Analysis of the structure of biomarker agreements with numerous real life case studies
Comprehensive access to over 1,000 actual biomarker deals entered into by the world’s biopharma companies, together with real world clause examples
Access to headline, upfront, milestone and royalty data
Full listing of biomarker deals by company A-Z, deal value, phase of development, deal type, and therapy focus
Identify leading biomarker deals by value since 2010
Identify the most active biomarker dealmakers since 2010
Detailed access to actual biomarker deals and contracts enter into by the leading fifty big pharma companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Biogen Inc.
  • Abbott Laboratories Ltd.
  • Diasorin
  • Sequenom
  • Bio-Rad Laboratories, Inc.
  • Scienion